WO1996001426A1 - Coffret permettant d'effectuer des etudes sur des hepatocytes - Google Patents

Coffret permettant d'effectuer des etudes sur des hepatocytes Download PDF

Info

Publication number
WO1996001426A1
WO1996001426A1 PCT/US1995/008209 US9508209W WO9601426A1 WO 1996001426 A1 WO1996001426 A1 WO 1996001426A1 US 9508209 W US9508209 W US 9508209W WO 9601426 A1 WO9601426 A1 WO 9601426A1
Authority
WO
WIPO (PCT)
Prior art keywords
assay
media
kit
cultivated
chee
Prior art date
Application number
PCT/US1995/008209
Other languages
English (en)
Inventor
Linda Mary Arterburn
Aaron Herman Heifetz
Joanne Zurlo
James Donald Yager
John Melvin Frazier
Original Assignee
W.R. Grace & Co.-Conn.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by W.R. Grace & Co.-Conn. filed Critical W.R. Grace & Co.-Conn.
Priority to AU29532/95A priority Critical patent/AU2953295A/en
Publication of WO1996001426A1 publication Critical patent/WO1996001426A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • This invention relates in general to mammalian cell cultures and more specifically to a hepatocyte test kit for morphological, physiological and pathophysiological testing.
  • liver function including hepatotoxicity
  • alternatives are being sought for humane and financial reasons.
  • a primary alternative of particular value would be a hepatocyte in vitro test kit which mimics in vivo conditions, wherein the hepatocytes are well characterized, healthy, highly differentiated, and have morphology and function of hepatocytes .in vivo.
  • the liver serves many functions, among them macromolecular synthesis, energy generation and storage, catabolism, and biotransformation of toxic substances and waste products of intermediary metabolism.
  • the hepatic parenchyma is comprised of three major cell types: hepatocytes, biliary epithelial cells, and Kupffer cells. Hepatocytes comprise about 80 percent of total liver mass.
  • the biochemical function of the liver includes the metabolism of amino acids, ammonia, proteins, carbohydrates, and lipids, biochemical oxidation, and the metabolism and detoxification of drugs, vitamins, and hormones. Current liver testing has led to the following generalities. Since the liver plays a major role in generalized metabolic events, acute or chronic liver dysfunction in many instances leads to biochemical abnormalities.
  • liver function tests based on biosynthesis or metabolic activity are of limited value.
  • some functions of the liver are more sensitive to injury than others, making detection and thus prevention difficult if not impossible.
  • the liver performs many varied functions, and no one test measures total liver function. Therefore, an understanding of the many known biochemical and metabolic functions of this organ is a prerequisite to identifying, analyzing and hopefully preventing or treating chronic or acute liver failure. Thus, it is a general objective of the present invention to gain insight into the biochemical and metabolic functions of the liver and effect of drugs on chemicals thereon. In addition, it is a primary objective of the present invention to produce an in vitro test kit which reduces animal testing and is of predictive value to humans. A further objective of the present invention is to establish a hepatocyte test kit which assesses liver physiology.
  • a still further objective is to provide a test kit which assesses liver pathophysiology. According to the Federal Register, more than 70,000 chemical compounds were commercially introduced in 1978, and between 700 and 3,000 new chemicals are introduced each year. From these only 6,000 were subjected to toxicity studies and then only to animals. Moreover, over 60,000 chemicals remained untested in animals or humans. This statistic highlights the necessity for a kit which ascertains toxins and/or toxic values in the liver and yields results which are applicable to humans.
  • a still further objective is to provide for a liver test kit which detects slight pathophysiological changes, wherein the hepatocytes are highly differentiated in morphology and function so that slight morphological and/or physiological changes are detectable.
  • a still further objective is to provide for a test kit which comprises long-term surviving hepatocytes.
  • the currently available hepatocyte culture media comprise synthetic formulations including glucose, salts, amino acids, vitamins, growth factors, etc.
  • the major drawback of hepatocytes culture systems based on these simple media, is that the hepatocytes do not survive more than two days in vitro. By survival, we mean maintenance of in vivo morphological expression and/or differentiated function. Without in vivo morphology and function, results are less significant.
  • a still further objective is to provide for a hepatocyte test kit capable of testing a wide variety of compounds.
  • a still further objective is to provide for a hepatocyte test kit which is sensitive to direct and indirect hepatotoxins.
  • Prior art attempts to increase the survival of cultivated hepatocytes include improving the culture medium or the substratum of the culture dishes, as described in U.S. Patent 4,914,032 and 5,030,105, both issued to Kuri-Harcuch, et al. These patents disclose hepatocyte cells at a density from about 180 to about 65,000 cells/cm 2 in a culture medium containing from about 1 to about 100 ug/ml of hydrocortisone, in the presence of either fibroblast cells treated to prevent their multiplication and to maintain normal morphology and expression of hepatocyte function for long periods, or fibroblast cell products on a modified substrate, at controlled densities from about 30,000 to about 65,000 cells/cm 2 .
  • the drawback of such a system is that more than one cell type is present and the test of experimental results are therefore more difficult to interpret and less consistent.
  • Matrigel a basement membrane-like mixture, in the medium.
  • cells are difficult to harvest from the gel and Matrigel is very expensive or laborious to obtain.
  • Matrigel may differ from lot to lot and as such is difficult to consistently reproduce.
  • a cell isolation technique comprising the use of an enzyme, collagenase, crude or purified, which produced a suspension of cells which were 95% intact, was disclosed in Seglen, P.O. Experimental Cell Research 82:391-398, 1973.
  • Basal culture conditions and more specifically the induction of cytochrome P-450 were disclosed in Waxman, D.J., Morrissey, J.J., Naik, S. and Jauregui, H.O.
  • DMSO dimethylsulfoxide
  • hepatocyte test kit comprising primary hepatocytes plated in crosslinked collagen coated housings and cultivated in media comprising Chee's Essential Media supplemented with from about 0.2 to about 20 mM glutamine, from about 0.1 to about 10 mM arginine, from about 1.0 to about 100 ⁇ M thymidine, from about 1.0 to about 100 ⁇ g/ml gentamicin, from about 2 to about 100 mM sodium bicarbonate, from about 1 to about 50 ⁇ g/ml insulin, from about 1 to about 50 ⁇ g/ml transferrin, and from about 1 to about 50 ng/ml selenious acid.
  • the medium is preferably further supplemented with from about 0.1 to about 10 ⁇ M dexamethasone and from about 0.5 to about 2% DMSO at a density from about 25,000 to about 250,000 cells/cm 2 . These conditions are referred to herein as CDDP conditions.
  • the test kit may further contain specific assay media and reagents, various toxin standards, quality control information, sample test results and instructions. BRIEF DESCRIPTION OF THE FIGURES
  • Fig. 1 depicts a preferred embodiment of the test kit.
  • Fig. 2a, b, c, d and e are micrographs illustrating the morphological characteristics of the CDDP-1 hepatocyte.
  • Fig. 3 depicts cytochrome P450 activity in CDDP-1 cultured hepatocytes at various culture times.
  • Fig. 4 depicts albumin synthesis results.
  • Fig. 5 depicts ⁇ -Naphthofavone- and Phenobarbital- mediated inductions of cytochrome P450.
  • Fig. 6 depicts acetaminophen cytotoxicity results.
  • Fig. 7 depicts carbon tetrachloride cytotoxicity results.
  • Fig. 8a, b, c and d depicts cytotoxicity results of numerous chemicals.
  • Fig. 9 depicts phase II conjugating enzyme activity.
  • Fig. 10 illustrates a low spontaneous death rate for CDDP-1 cultured hepatocytes.
  • Fig. 11 depicts the ability to detect slight structural changes by the test kit.
  • the present invention advantageously allows for the prolonged survival of in vitro cultivated hepatocytes and as a result the use of said hepatocytes in a novel kit for testing liver morphology, physiology and pathophysiology.
  • the increased survival rate allows for morphological and physiological studies alone or in response to drugs, chemical compounds, toxins, etc. Since one of the functions of the liver is the elimination of toxic substances which may take prolonged periods of time, it is very advantageous to have long lived functioning hepatocyte cultures for extended study.
  • the CDDP test kit provides for such cultures.
  • the CDDP test kit may be used to detect compounds which cause or are associated with cytotoxicity, necrosis, cholestasis, carcinogenic potential, unscheduled DNA synthesis, liver growth or regeneration, growth inhibition, hepatocyte differentiation or de-differentiation, hepatic failure, altered hepatic metabolism, viral infectivity, etc.
  • the CDDP test kit may also be used to study: metabolism of xenobiotics, drugs or endogenous compounds, mechanisms of toxicity, energy metabolism, hepatocyte structure and function, hepatic synthetic functions, hepatocyte differentiation, hepatocyte gene regulation, hepatic enzyme activity, etc.
  • the possible agents which may be tested with the kit comprise pharmaceutical drugs or drug candidates, new formulations of drugs, biomedical material extracts, industrial or household chemicals, detergents, consumer products and formulations, environmental pollutants, biological fluids, etc.
  • the test kit contemplated by the present invention comprises primary hepatocytes plated on crosslinked collagen coated housings and cultivated in media comprising Chee's Essential media (a media produced by GIBCO Laboratories, Life Technologies, Inc., and known as Formula #88-5046) supplemented with from about 0.2 to about 20 mM glutamine, from about 0.1 to about 10 mM arginine, from about 1.0 to about 100 ⁇ M thymidine from about 1.0 to about 100 ⁇ g/ml gentamicin, and from about 2 to about 100 mM sodium bicarbonate.
  • Chee's Essential media a media produced by GIBCO Laboratories, Life Technologies, Inc., and known as Formula #88-5046
  • the medium is preferably further supplemented with from about 1 to about 50 ⁇ g/ml insulin, from about 1 to about 50 ⁇ g/ml transferrin, and from about 1 to about 50 ng/ml selenious acid.
  • the medium is preferably yet further supplemented with from about 0.1 to about 10 ⁇ M dexamethasone and from about 0.5 to about 2% DMSO.
  • Hepatocytes are preferably plated on the housings at a density from about 25,000 to about 250,000 cells/cm 2 .
  • Chee's Essential Media supplemented with the aforementioned will hereinafter be referred to as modified CEM.
  • the test kit may further contain specific assay media and reagents, various toxin standards, quality control information, sample test results and instructions.
  • the primary hepatocytes are prepared and cultured under the following conditions.
  • Hepatocytes are isolated from mature male or female rats using a two- step perfusion method as described by Seglen, P.O., Experimental Cell Research 82:391:398, hereby incorporated by reference.
  • the two-step perfusion method entails removing Ca 2+ followed by enzymatic treatment.
  • collagenase crude or purified
  • all the parenchymal tissue is converted to a suspension of cells which is 95% intact.
  • differential centrifugation o enrich parenchymal hepatocytes. Differential centrifugation purifies the parenchymal cells from non-parenchymal cells.
  • the substratum is prepared with a crosslinked collagen.
  • Collagens contemplated for use in the present invention include, but are not limited to, the following: rat tail collagen, Vitrogen 100TM (a trademark of Celtrix Pharmaceuticals Inc., Santa Clara, CA) , and bovine dermal collagen; Vitrogen, a highly purified bovine collagen preparation, is particularly preferred.
  • the selected collagen may then be poured or coated onto a housing, that may include, for example: flasks, multi-well dishes, petri dishes, etc.
  • housings used in the present invention be made from polymethyl pentene or polystyrene, and most preferred that polymethyl pentene housings, such as PermanoxTM dishes (available from Nunc, Inc., Naperville, IL) , be used.
  • the culture medium comprises Chee's Essential Media which is supplemented with from about 0.2 to about 20 mM glutamine, from about 0.1 to about 10 mM arginine, from about 1.0 to about 100 ⁇ M thymidine, from about 1.0 to about 100 ⁇ g/ml gentamicin, and from about 2 to about 100 mM sodium bicarbonate. It is preferably further supplemented with from about 1 to about 10 ⁇ g/ml insulin, from about 1 ⁇ g/mg to about 10 ⁇ g/ml transferrin, and from about 1 ng/ml to about 50 ng/ml selenious acid.
  • DMSO dimethyl sulfoxide
  • Chee's Essential Media is supplemented with 2 mM glutamine, 1 mM arginine, 41.3 ⁇ M thymidine, 26.2 mM sodium bicarbonate, and 50 ⁇ g/ml gentamicin, 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 5 ng/ml selenious acid, 1 uM dexamethasone and 1% DMSO.
  • the particular supplement, and its quantity, is dependent on the assay to be performed; the selection of the supplement is readily ascertainable by one skilled in the art.
  • Hepatocytes isolated by the aforementioned method are then introduced into modified CEM at a density of from about 100,000 to about 2,000,000 cells/ml.
  • the cell suspension is then pipetted or poured into the aforementioned subtratum-coated housing to achieve a density of from about 25,000 to about 250,000 cells/cm 2 .
  • the hepatocytes are then adhered to the housing by incubating them at about 35-40°C for at least 30 minutes, at from about 80 to 100% humidified C0 2 :air atmosphere.
  • the media may then be aspirated and replaced with fresh modified CEM culture media to remove any unattached cells.
  • the media may be replenished at intervals of from about 6 to about 48 hours thereafter.
  • Hepatocytes cultivated under this method will hereinafter be referred to as CDDP hepatocytes.
  • the test kit is comprised of the CDDP hepatocytes and specific assay media and reagents, various toxin standards, quality control information, sample test results and instructions (see Fig. 1) .
  • Assay media contemplated for use in the present invention include, but are not limited to, the following: Chee's media, William's media, Waymouth's Media, Dulbecco' s Modified Eagle Media, RPMI media. A detailed listing of media and their composition can be found in the 1990 Gibco BRL Catalogue & Reference Guide, Life Technologies, Inc., Research Products Division, hereby incorporated by reference.
  • Reagents contemplated for use with the present invention include chemicals and biological fluids.
  • Biological fluids contemplated include, but are not limited to, serum, plasma, and exudate.
  • the chemical reagents contemplated generally fall into three classes.
  • the first class of chemical reagents comprises chemicals which are not metabolized but are eventually eliminated from the body in an unaltered form. These chemicals are hereinafter referred to as direct toxins. These may include, for example, drugs such as cadmium chloride, phalloidin, phosphorous, ethionine, alpha a anitine, etc.
  • the second class of chemical reagents comprises chemicals which are biotransformed, but whose metabolites have a similar level of toxicity to the parent compound.
  • the parent compound is metabolized, but the metabolism is not critical to the toxicity of the compound.
  • drugs such as substituted alkyl carbon systems comprising substituted alkanes, haloalkanes, vicinal dihaloalkanes, heteroatom-substituted cyclopropyls; olefinic carbon systems comprising olefins, haloalkenes, dihydrofurans, ; aromatic carbon systems comprising; polycyclic aromatic hydrocarbons, halobenzenes, alkenylbenzenes, acetanilides, furans, pyrroles, thiophenes; nitrogen based systems comprising nitrosamines, pyrrolines, aminofluorenes, aromatic amines, azo dyes, hydrazines,
  • the third class of chemical reagents comprises chemicals which are not toxic until they are metabolized, hereinafter referred to as indirect toxins.
  • the present invention is particularly advantageous with this group of chemicals because toxicity can only be determined with fully functioning cells.
  • Illustrative drugs in this class comprise acetaminophen, cyclophosphamide, aflatoxin Bl, alkylnitrosamine, allyl compounds, allyl-isopropyl- acetamide, amino-azo dyes, bromobenzene, carbon tetrachloride and other haloaliphatic compounds, carcinogenic polycyclic hydrocarbons, chloramphenicol, cycasin, ethanol, furosemide, fluroxene, halothane, isoniazid, methoxyflurane ngaione, pyrrolidizine alkaloids, safrole, thioacetamide, urethane, etc.
  • test kit of the present invention is for cytotoxicity testing.
  • the general protocol for such testing is described as follows. Specific protocols may vary depending upon the test reagent used.
  • CDDP hepatocytes are dosed with the selected reagent for a period of time sufficient to provide an effective dose.
  • the effective dose for a particular reagent is a function of sample concentration and dose time, and may be determined by initial range finding studies. Although the effective dose will likely be different for different reagents, the procedures for determining the effective dose of a particular reagent or toxin are well known in the art. Cellular viability is then tested using one or more of the included assays. These are further discussed below.
  • cytotoxicity testing using the instant test kit will follow generally accepted laboratory procedures including the preparation of separate experimental cultures and controls.
  • Experimental cultures are prepared by aspirating and replacing the culture media in the CDDP housing with fresh modified CEM that has been prewarmed to a temperature of approximately 35°- 40°C, and preferably to approximately 37°C.
  • the modified CEM here, may be prepared without dexamethasone and/or DMSO.
  • the test reagent is then added to the experimental cultures at a concentration level and for a dosing time sufficient to obtain an effective dose. Preparation of test reagent samples for such purpose is well known in the art.
  • the toxin diazepam may be prepared in an ethanol stock solution at about a 100 mM concentration and added to the culture until final ethanol concentration reaches 1%, e.g. about 1 mM final diazepam dosing concentration.
  • cyclophosphamide may be prepared in water at about a 143 mM concentration and then added to the culture to provide a several millimolar concentration;
  • acetaminophen may be added in powder form to modified CEM, incubated until dissolved, to prepare a 20 mM stock solution, and then added to the culture;
  • cadmium chloride may be prepared in saline at about a 100 mM concentration, and then further diluted in modified CEM before adding to the culture.
  • Control cultures may be prepared by aspirating and replacing the culture media with fresh modified CEM, as provided above (for experimental cultures) , or with vehicle control.
  • Vehicle controls may contain, in addition to fresh modified CEM, up to 1% ethanol or other alcohol, encapsulated drugs, liposomes, up to 2% DMSO, and up to 10% saline or water.
  • the cultures are then incubated at approximately 35°-40°C, and preferably at 37°C, in a humidified C0 2 :air atmosphere.
  • the cultures are thereafter analyzed with morphological and/or physiological assays to determine toxicity.
  • Morphological or physiological scoring may be accomplished by a variety of assay including, but not limited to, the following: the 3- [4, 5-dimethylthiazol- 2-yl] -2, 5-diphenyltetrazolium bromide assay (hereinafter referred to as MTT) , for assessing mitochondrial function; the neutral red uptake assay for lysosomal integrity assessment, the lactate dehydrogenase release assay (hereinafter LDH) for plasma membrane integrity assessment, the Alanine Aminotransferase Release assay (hereinafter ALT) for plasma membrane integrity assessment, the glutathione depletion assay, the lipid peroxidation assay, the total protein assay, cytochrome P450 activity assays, albumin assays, bile acid production, secretion or flow ⁇ 7
  • MTT 5-diphenyltetrazolium bromide assay
  • the MTT viability assay measures reduction of MTT by mitochondrial succinate dehydrogenase in live cells to an insoluble blue formazan salt.
  • the formazan salt is extracted from the cells with isopropanol and the color is quantified by spectrophotometer.
  • the MTT assay yields relative viability data by giving the percentage of live cells in the test culture versus the percentage of live cells in the control culture.
  • MTT stock solution is prepared by dissolving MTT in phosphate buffered saline (hereinafter PBS) in a ratio of 5 mg:l ml.
  • PBS phosphate buffered saline
  • the stock solution is further diluted 1:10 in modified CEM culture medium, usually lacking hormones and DMSO, to prepare the working solution.
  • the media is first removed from control culture(s); then Triton X100TM (trademark of the Rohm & Haas Co. and generically known as octylphenoxpolyethoxyethanol) , preferably a 1% solution, is added to the attached cells and swirled for 10-20 minutes at 50-200 rpm, and preferably for about 15 minutes at approximately 100 1
  • Triton X100TM trademark of the Rohm & Haas Co. and generically known as octylphenoxpolyethoxyethanol
  • the media is removed from the toxin treated cultures and remaining control cultures and the cells are rinsed with warmed PBS and treated with working solution. It is preferred that the cells remain moist at all times.
  • the cultures are then incubated at 35°-40°C for 30-60 minutes and preferably at about 37°C for 45 minutes.
  • the MTT solution is then removed without rinsing the cells, because the cells may detach from the dish. Thereafter, isopropanol is added to each culture and swirled under conditions sufficient to solubilize and extract dye from the cells, preferably at about 100 rpm for approximately 10 minutes.
  • % viable cells may be calculated from the following formula:
  • % viable cells ABS 560 sample - blank x 100
  • a dose response curve may be plotted from the aforementioned formula to obtain an effective concentration at 50% of the dose eliciting the response.
  • the 100% lysis control should show no viable cells.
  • the MTT assay may be used to quantify the actual number of live cells . To use this methodology, the cells are stained, as described above, followed by the addition of fresh PBS to each culture. The cells are then photographed under a light microscope, without phase contrast. Viable cells are represented by the percentage of the number of stained cells to the total cells in the field.
  • the LDH assay measures cellular viability as a function of plasma membrane integrity.
  • Lactate dehydrogenase (LDH) a soluble cytosolic enzyme of the glycolytic cycle, is retained in live cells but is released into the surrounding culture media by dead cells through their disrupted membranes .
  • LDH reagents a quantitative spectrophotometric kinetic LDH enzyme assay is performed. The amounts of LDH in cells and the media are measured and compared to give an indication of the proportion of dead cells.
  • the LDH assay is performed using reconstituted LDH reagent (Sigma Catalog No. 228-10) and Triton X100TM.
  • Reconstituted LDH reagent is prepared by adding distilled water to each reagent bottle and warming the bottles to about 30°C. The assay is begun by removing and saving culture media from cells to be tested. Then, a solution of 1% Triton X100TM is added and swirled with attached cells 10-30 minutes at 50 to 200 rpm and preferably for about 10 minutes at about 100 rpm. A portion of the media or Triton extract is then transferred to a well plate and warmed to about 30°C. Reconstituted LDH assay reagent is added to each well. Using a Molecular Device Place Reader for Dual Kinetics, programmed to the following parameters, read kinetics and subtract any controls from all readings:
  • % Cell Viability 100 - % LDH
  • Vmax maximum velocity of enzyme reaction.
  • a dose response curve may be plotted for % LDH in media vs. toxin concentration to obtain the effective concentration which elicits 50% of the maximal LDH release.
  • the invention is further illustrated by reference to the following Examples and Figures .
  • Example 1
  • Hepatocytes were isolated from the livers of mature male Fischer rat (between 200-250 g, purchased from Charles River Labs, Wilmingham, MA) , using the two step collagenase perfusion method as described by Seglen, EXP. Cell Res. 82:391-398 (1973), and as further provided above. Once isolated, the hepatocytes were subjected to differential centrifugation three times for five minutes each at 50 x g.
  • a substratum was prepared by coating Vitrogen on Permanox plastic petri dishes using morphocarbodi-imide (Aldrich, no. CIO, 640-2) as the coupling agent. Vitrogen was diluted to 100 ⁇ g/ml in aqueous solution of morpho carbodi-imide (130 ⁇ g/ml, final concentration) , and the resulting solution was coated on the tissue culture plates at 2 ml/60 mm plate. The plates were thereafter incubated overnight at 37°C. Unbound collagen was thereafter removed by aspiration, and the plates were rinsed once with phosphate buffered saline (PBS) and stored at 4°C until used.
  • PBS phosphate buffered saline
  • the culture media comprised Chee's Essential Medium (CEM) supplemented with 2 mM glutamine, 1 mM arginine, 41.3 ⁇ M thymidine, 26.2 mM sodium bicarbonate, 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 5 ng/mg selenious acid, 50 ⁇ g/ml gentamicin, 1 ⁇ M dexamethasone and 1% dimethyl sulfoxide (DMSO) .
  • CDDP-1 culture media This media is hereinafter referred to as CDDP-1 culture media.
  • Hepatocytes isolated as previously described were therafter diluted into the CDDP-1 culture medium at 6.25 x 10 5 cells/ml, and 4 mis of cells (2.5 x 10 6 cells) were seeded onto the aforementioned substratum, the final density being about 120,000 cells/cm 2 .
  • the coated dishes were then incubated at 37°C in a 19:1 atmosphere of air:C0 2 and a relative humidity of 95% for 2 hours for cell attachment. Culture media was changed after the attachment period and every 48 hours thereafter using fresh CDDP-1 culture media.
  • CDDP-1 hepatocytes Hepatocytes cultivated under the aforementioned method are hereinafter referred to as CDDP-1 hepatocytes.
  • CDDP-1 hepatocytes were analyzed for morphological and metabolic characteristics, as follows, using light micrographs, scanning electron micrographs and transmission electron micrographs. The results showed that the CDDP-1 hepatocytes have a differentiated morphology that mimics in vivo hepatocytes .
  • FIG. 2a and b are light micrographs illustrating the morphological differences between a prior art primary rat hepatocyte monolayer culture (Fig. 2a) and a CDDP-1 hepatocyte (Fig. 2b) .
  • the prior art hepatocyte has a flat and spread de-differentiated morphology
  • the CDDP-1 hepatocyte has a cuboidal and differentiated morphology which mimics in vivo hepatocytes.
  • the CDDP-1 hepatocytes cluster into strands which are reminiscent of the trabecular structures formed by hepatocytes in vivo.
  • Fig. 2a and b are light micrographs illustrating the morphological differences between a prior art primary rat hepatocyte monolayer culture (Fig. 2a) and a CDDP-1 hepatocyte (Fig. 2b) .
  • the prior art hepatocyte has a flat and spread de-differentiated morphology
  • the CDDP-1 hepatocyte has a cub
  • FIG. 2c is a Scanning Electron Micrograph (SEM) illustrating the 3D nature of the cells and the numerous microvilli that stud the surface of the cells.
  • Fig. 2d is a transmission electron micrograph of a bile canaliculus (BC) formed between adjacent CDDP-1 hepatocytes. Actin filaments visualized by phalloidin rhodamine fluorescence aggregate at the apical
  • Fig. 2e is a scanning electron micrograph showing fibrin clots synthesized by CDDP-1 hepatocytes. These clots are resistant to 1M urea, a chaotropic agent, suggesting that the CDDP-1 hepatocytes produce a number of clotting factors in vitro. Production and secretion of clotting factors into the plasma is a primary function of hepatocytes in vivo.
  • CDDP-1 hepatocytes were then tested for metabolic characteristics by analysis of cytochrome P450 activity and evaluation of albumin synthesis. P450 Activity
  • Fig. 3a depicts cytochrome P450 activity in CDDP-1 cultured hepatocytes at various culture times .
  • the P450 activity was assessed by testing for ethoxyresorufin O-deethylase (EROD) activity, which is a specific function of the P450 1A1/1A2 subfamily of proteins (Fig. 3a) . Note the slight induction of the activity after 3 and 6 days.
  • EROD ethoxyresorufin O-deethylase
  • P450 2B1/2B2 isozyme activity was tested by measuring pentoxyresorufin O-dealkylase (PROD) activity (Fig. 3b) . Note only a minimal decline in the activity of this enzyme with culture age.
  • P450 3A activity was assessed by measuring the hydroxylation of nordiazepam (Fig. 3c) . Note the glucocorticoid induction of this enzyme by day 3 and 6.
  • the activity of P450 2E1 activity was measured as the 6-hydroxylation of chlorzoxazone (Fig. 3d) . Note that this activity is maintained for up to 3 days, with maintenance of approximately 60% activity at day 6. Thus while prior art cultivated hepatocyte systems lose between 50-80% of their P450 activity within the first 24-48 hours of culture, the hepatocytes of the present invention maintained a majority of their P450 activity for at least 6 days in culture. This continued cytochrome activity is of enormous value to the in vitro study of liver physiology in general and more specifically for metabolism and cytotoxicity studies. Albumin Synthesis
  • Albumin content was measured in a 24 hour culture medium with an enzyme linked immunosorbent assay (ELISA) .
  • ELISA enzyme linked immunosorbent assay
  • cytochrome P450 activity was induced using ⁇ -Naphthoflavone and phenobarbital, respectively.
  • Fig. 5a and b illustrate that like in vivo hepatocytes, the cultured hepatocytes are inducible for cytochrome P450 activity in vivo with these classical inducer chemicals.
  • prior art hepatocyte cultures are refractory to induction of P450 enzymes in vitro.
  • Fig. 5a illustrates that the P450 1A1/2 EROD activity is increased 20 times after exposure of the cultures to 25 mM ⁇ -naphthoflavone for a three day period.
  • Fig. 5b illustrates that P450 2B1/2 pentoxyresorufin O-dealkylaltion (PROD) activity is induced by a factor of 7 after exposure to 1 mM phenobarbital for 4 days.
  • the test kit may consequently comprise ⁇ - naphthoflavone and phenobarbital as reagents allowing the user to test for liver cytochrome P450 induction caused by these drugs.
  • APAP hepatotoxin acetaminophen
  • Hepatocytes cultured using conventional techniques show low levels of P450 activity and a moderate sensitivity to this toxin, whereas CDDP-1 cultures show high levels of P450 activity and are most sensitive to APAP toxicity.
  • the figure illustrates the advantage of using CDDP-1 cells which maintain P450 function for toxicology studies.
  • CC1 4 The toxicity of CC1 4 is dependent on the maintenance of P450 2E1 activity which activates this chemical to a toxic metabolite. Hepatocytes were treated with 10 mM CC1 4 for 60 minutes and toxicity was assessed 19 hours later by LDH release (Fig. 7) . The control represents spontaneous release of LDH. The results show that CC1 4 is significantly more toxic to CDDP hepatocytes in which P450 activity is maintained than to prior art hepatocytes which did not maintain P450 activity.
  • CDDP-1 hepatocytes cultured for 2 days were treated with acetaminophen, chlorpromazine, promazine, diazepam, galactosamine, thioacetamide, CdCl 2 , naphthalene, ferrous sulfate or amitriptyline, for a 20 hour period. Thereafter the percentage of dead cells was calculated from the release of LDH into the medium or by measuring MTT reduction.
  • Fig. 8a illustrates representative dose-response curves for the LDH assay, as well as the effective concentration for 50% cytotoxicity (EC50) for various chemicals (Fig. 8b) .
  • Fig. 8c dose response curves
  • Fig. 8d EC50
  • Phase II conjugating enzymes play a major role in many detoxification reactions. It is therefore important to maintain their activity to assess detoxification.
  • Figs. 9a, b, and c illustrate that Phase II enzyme activity also remains intact in the CDDP-1 cultured hepatocytes. The combination of Phase I and Phase II enzyme activity is important to get complete metabolism of xenobiotics and to manifest toxicity of chemicals that require bioactivation.
  • CDDP-1 hepatocytes suffer only a small initial drop in UDP-glucuronyltransferase (Fig. 9a) and glutathione S-transferase activities (Fig. 9b) , and recover to near original levels by the third and sixth day of culture.
  • Fig. 9c illustrates that cellular glutathione levels are close to in vivo levels, 20 nmol/mg protein, after initial seeding and after 3 days in culture. Moreover, glutathione levels remain near 50% in vivo values after 6 days in culture.
  • the present test kit may advantageously be used to verify whether the liver is capable of metabolizing a particular drug and if so, ascertain the optimal safe level .
  • Fig. 10a shows that lactate dehydrogenase (LDH) , a cytosolic enzyme released into the medium upon cell death as a function of the disruption of the cellular membrane, is low in the culture medium (light bars) relative to the amounts found inside the CDDP-1 hepatocytes (dark bars) . Moreover, the LDH content of the cells remain nearly constant indicating minimal cell loss or death.
  • LDH lactate dehydrogenase
  • the total amount of protein was also analyzed. As shown in Figure 10 (b) , the total amount of protein associated with each culture of cells remains constant throughout the culture period indicating minimal loss of cells due to cell death. This data demonstrates the advantageous long-term survival of the CDDP-1 hepatocytes, namely at least 10 days.
  • a toxicity test kit Since slight changes in chemical structure lead to significant differences in toxicity, it is advantageous for a toxicity test kit to detect slight changes.
  • the results in Fig. 11 demonstrate that the test kit of the present invention does detect small changes.
  • Fig. 11 shows that the novel test kit was able to differentiate between the toxicity of promazine and chlorpromazine, chemical structures which differ by a single chloride atom on the third ring.
  • the present invention comprises a hepatocyte test kit comprising primary hepatocytes cultivated in cross-linked collagen coated housings and cultivated in media comprising Chee's Essential Media supplemented with from about 0.2 to 20 mM glutamine, from about 0.1 to about 10 mM arginine, from about 1.0 to about 100 uM thymidine, from about 1.0 to about 100 ⁇ g/ml gentamicin, and from about 2 to about 100 sodium bicarbonate.
  • the media is preferably supplemented with from about 1 to about 10 ⁇ g/ml insulin, from about 1 ⁇ g/ml to about 10 ⁇ g/ml transferrin, and from about 1 ng/ml to about 50 ng/ml selenious acid. It is preferably further supplemented with from about 0.1 to about 10 ⁇ M dexamethasone and from about 0.5% to about 2% dimethyl sulfoxide (DMSO) .
  • DMSO dimethyl sulfoxide
  • Chee's Essential Media is supplemented with 2 mM glutamine, 1 mM arginine, 41.3 ⁇ M thymidine, 26.2 mM sodium bicarbonate, 50 ⁇ g/ml gentamicin, 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 5 ng/ml selenious acid, 1 ⁇ M dexamethazone and 1% DMSO.
  • the test kit may further contain specific assay media and reagents, various toxin standards, quality control information, sample test results and instructions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un coffret permettant d'effectuer des études in vitro sur des hépatocytes primaires étalés sur des supports portant un revêtement de collagène réticulé et cultivés dans un milieu essentiel de Chee additionné de glutamine, d'arginine, de thymidine, de bicarbonate de sodium, de gentamicine, d'insuline, de transferrine, d'acide sélénieux, de dexaméthazone et de DMSO. L'invention concerne également un procédé d'utilisation du coffret pour effectuer des études morphologiques, physiologiques et pathophysiologiques sur le foie.
PCT/US1995/008209 1994-07-01 1995-06-27 Coffret permettant d'effectuer des etudes sur des hepatocytes WO1996001426A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU29532/95A AU2953295A (en) 1994-07-01 1995-06-27 Hepatocyte test kit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26971494A 1994-07-01 1994-07-01
US08/269,714 1994-07-01

Publications (1)

Publication Number Publication Date
WO1996001426A1 true WO1996001426A1 (fr) 1996-01-18

Family

ID=23028384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008209 WO1996001426A1 (fr) 1994-07-01 1995-06-27 Coffret permettant d'effectuer des etudes sur des hepatocytes

Country Status (2)

Country Link
AU (1) AU2953295A (fr)
WO (1) WO1996001426A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055355A2 (fr) * 1999-03-17 2000-09-21 University Of North Carolina At Chapel Hill Procede de criblage de composes d'interet potentiel susceptibles d'etre excretes par les canalicules biliaires
WO2001096597A2 (fr) * 2000-06-13 2001-12-20 Glaxo Group Limited Procede de criblage a haut rendement de composes potentiels pour une activite biologique
EP1818392A1 (fr) * 2006-02-14 2007-08-15 Genetix Limited Support de culture de cellules
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914032A (en) * 1985-06-06 1990-04-03 Centro De Investigation Y Estudios Avanzados Del Instituto Politecnico Nacional Process for the long-term surviving culture of hepatocytes
DE4336399A1 (de) * 1993-10-26 1995-04-27 Augustinus Dr Med Bader Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914032A (en) * 1985-06-06 1990-04-03 Centro De Investigation Y Estudios Avanzados Del Instituto Politecnico Nacional Process for the long-term surviving culture of hepatocytes
DE4336399A1 (de) * 1993-10-26 1995-04-27 Augustinus Dr Med Bader Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.T. GUTSCHE ET AL.: "Synthesis and characterizationof polymer substrates for the rat hepatocyte culture", MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS, vol. 330, 1 June 1994 (1994-06-01), WASHINGTON DC USA, pages 243 - 248 *
J. GUILLEMETTE ET AL.: "Chracterization of the in vitro hepatocyte model for toxicological evaluation: repeated growth stimulation and glutathione response.", BIOCHEMISTRY AND CELL BIOLOGY, vol. 71, no. 1-2, MONTREAL CANADA, pages 7 - 13 *
S.F. MUAKKASSAH-KELLY ET AL.: "Long-term maintenance of hepatocytes in primairy culture in the presence of DMSO: further characterization and effect of nafenopin, a peroxisome proliferator.", EXPERIMENTAL CELL RESEARCH, vol. 171, NEW YORK NY USA, pages 37 - 51 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604934B2 (en) 1999-03-17 2009-10-20 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion by endogenous transport systems
EP1659403A3 (fr) * 1999-03-17 2006-07-05 University Of North Carolina At Chapel Hill Procédé de dépistage de la réceptivité à l'excrétion biliaire sur des composés candidats
US8367630B2 (en) 1999-03-17 2013-02-05 The University Of North Carolina At Chapel Hill Method for inhibiting expression of a protein in a hepatocyte
EP2293063A1 (fr) * 1999-03-17 2011-03-09 University Of North Carolina At Chapel Hill Procédé de criblage de composés candidats pour la sensibilité à la sécretion biliaire
US6780580B2 (en) 1999-03-17 2004-08-24 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
EP1659403A2 (fr) * 1999-03-17 2006-05-24 University Of North Carolina At Chapel Hill Procédé de dépistage de la réceptivité à l'excrétion biliaire sur des composés candidats
WO2000055355A3 (fr) * 1999-03-17 2000-12-14 Univ North Carolina Procede de criblage de composes d'interet potentiel susceptibles d'etre excretes par les canalicules biliaires
US7682781B2 (en) 1999-03-17 2010-03-23 The University Of North Carolina At Chapel Hill Method of screening a metabolite of a parent candidate compound for susceptibility to biliary excretion
EP2112511A1 (fr) * 1999-03-17 2009-10-28 University Of North Carolina At Chapel Hill Procédé de dépistage de la réceptivité à l'excrétion biliaire sur des composés candidats
WO2000055355A2 (fr) * 1999-03-17 2000-09-21 University Of North Carolina At Chapel Hill Procede de criblage de composes d'interet potentiel susceptibles d'etre excretes par les canalicules biliaires
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
WO2001096597A3 (fr) * 2000-06-13 2003-09-12 Glaxo Group Ltd Procede de criblage a haut rendement de composes potentiels pour une activite biologique
WO2001096597A2 (fr) * 2000-06-13 2001-12-20 Glaxo Group Limited Procede de criblage a haut rendement de composes potentiels pour une activite biologique
EP1818392A1 (fr) * 2006-02-14 2007-08-15 Genetix Limited Support de culture de cellules

Also Published As

Publication number Publication date
AU2953295A (en) 1996-01-25

Similar Documents

Publication Publication Date Title
Guillouzo Liver cell models in in vitro toxicology.
Guillouzo et al. Use of human hepatocyte cultures for drug metabolism studies
Xu et al. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. I. Glucose metabolism and enzyme release as cytotoxic markers
LeCluyse et al. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes
Grant et al. Human adult hepatocytes in primary monolayer culture: maintenance of mixed function oxidase and conjugation pathways of drug metabolism
Josse et al. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies
Grisham Cell types in long‐term propagable cultures of rat liver
Segner Isolation and primary culture of teleost hepatocytes
Koebe et al. Collagen gel immobilization: a useful cell culture technique for long-term metabolic studies on human hepatocytes
Rogiers et al. Phase I and phase II xenobiotic biotransformation in cultures and co-cultures of adult rat hepatocytes
Luttringer et al. Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes
Lagadic-Gossmann et al. Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture
George et al. Time-dependent expression of cytochrome P450 genes in primary cultures of well-differentiated human hepatocytes
Segner et al. Metabolic activity in primary cultures of fish hepatocytes
US20130344154A1 (en) Immortal Unipotent Porcine PICM-19H and PICM-19B Stem Cell Lines
Modriansky et al. Human hepatocyte-A model for toxicological studies. Functional and biochemical characterization
Schaffert et al. WIF-B cells as a model for alcohol-induced hepatocyte injury
Palmeira et al. Mercuric chloride toxicity in rat liver mitochondria and isolated hepatocytes
McCloskey et al. Resistance of three immortalized human hepatocyte cell lines to acetaminophen and N-acetyl-p-benzoquinoneimine toxicity
Driscoll et al. Phenolsulfonphthalein (phenol red) metabolism in primary monolayer cultures of adult rat hepatocytes
WO1996001426A1 (fr) Coffret permettant d'effectuer des etudes sur des hepatocytes
Washizu et al. Long-term maintenance of cytochrome P450 activities by rat hepatocyte/3T3 cell co-cultures in heparinized human plasma
Taylor et al. Comparative cytotoxicity of monocrotaline and its metabolites in cultured pulmonary artery endothelial cells
Maier Development of in vitro toxicity tests with cultures of freshly isolated rat hepatocytes
Roberts et al. Inducibility of enzyme activities associated with the cytochrome P-450 1A family, ethoxyresorufin O-deethylase, and methoxyresorufin O-demethylase in human hepatocyte lines derived from normal liver tissue.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 96503921

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 96503921

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 96503921

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1996503921

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1996503921

Format of ref document f/p: F